跳至主要内容
临床试验/NCT07150221
NCT07150221Enrolling By Invitation不适用

Post-Market Clinical Follow-Up Study of the Vivacit-E Vitamin E Highly Crosslinked Polyethylene HXLPE Elevated Liners in Primary THA- A Retrospective Enrollment/Prospective Follow-Up Study

Zimmer Biomet1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2025年10月10日最近更新:

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
Zimmer Biomet
入组人数
52
试验地点
1
主要终点
Survival of the Implant System via Adverse Events

研究概览

简要总结

The main objective of this study is to confirm long-term safety, performance, and clinical benefits of the Vivacit-E Vitamin E HXLPE Elevated Liners when used in primary total hip arthroplasty.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient was 18 years of age or older and skeletally mature at the time of surgery
  • Patient qualified for and underwent surgical procedure with a Vivacit-E Vitamin E HXLPE Elevated Liner to treat one of the following indications in primary THA:
  • Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
  • Protrusio acetabuli
  • Traumatic arthritis
  • Slipped capital epiphysis
  • Fused hip
  • Fracture of the pelvis
  • Diastrophic variant
  • Patient underwent surgical procedure 10 years (+ no maximum/- 182 days) prior to date of study consent
  • Patient is will and able to sign IRB approved Informed Consent Form or provide verbal consent

排除标准

  • Off label use or not according to the approved IFU at the time of surgery
  • Patient presented with any of the following at the time of the surgical procedure:
  • Osteoradionecrosis
  • Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation
  • Systemic or local infection
  • Revision procedure where other treatment or devices have failed*
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
  • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions
  • For the purpose of this clinical study; a revision procedure refers to a procedure in which the prior procedure on the ipsilateral hip utilized a similar approach (i.e., primary total hip arthoplasty)

结局指标

主要结局

Survival of the Implant System via Adverse Events

时间窗: 10 years

The primary endpoint is defined by the survival of the implant system at 10 years post-operative, which is based on removal of the study device and will be determined using the Kaplan Meier method. The safety of the study device will be assessed by monitoring the frequency and incidence of adverse events.

次要结局

  • Pain and functional performance measured by the Oxford Hip Score(10 years)
  • Subject quality-of-life measured by the EQ-5D-5L(10 Years)

研究者

发起方
Zimmer Biomet
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验